StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) stock

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.78−0.09 (-1.85%)

Close on Nov 18, 2026Market cap $789.85MP/E 6.2Yield –

Ironwood Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Ironwood Pharmaceuticals's pe ratio was 6.2× on Nov 10, 2026, against 23.3× a year earlier. Over the last 5 years it ranged from 3.4× to 161.0×, with a median of 13.0×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 10, 20266.2×−16.2
2025Dec 31, 202522.5×−76.3
2024Oct 31, 202498.8×+87.8
2023Jul 31, 202311.0×−2.1
2022Dec 30, 202213.0×+9.5
2021Dec 31, 20213.6×−12.9
2020Dec 31, 202016.5×–

More Ironwood Pharmaceuticals figures

See a number that looks wrong?